Jazz Pharmaceuticals (JAZZ) EPS (Weighted Average and Diluted) (2010 - 2026)
Jazz Pharmaceuticals' quarterly EPS (Weighted Average and Diluted) came in at $4.43 in Q1 2026, up 391.45% year-on-year from $0.9 in Q1 2025, and up 32.63% quarter-over-quarter from $3.34 in Q4 2025.
Jazz Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 17 years, with the latest figure at $4.43 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 391.45% year-over-year to $4.43; the trailing twelve-month figure through Mar 2026 stood at $0.11 (down 98.52% YoY), and the FY2025 full-year result was -$5.84, down 167.51% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $4.43, up from $3.34 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $4.43 in Q1 2026, with the low at -$11.74 in Q2 2025.
- Average EPS (Weighted Average and Diluted) over 5 years is $0.58, with a median of $1.43 recorded in 2023.
- Year-over-year, EPS (Weighted Average and Diluted) slumped 611.11% in 2022 and jumped 3366.67% in 2023.
- Tracing JAZZ's EPS (Weighted Average and Diluted) over 5 years: stood at -$3.84 in 2022, then soared by 137.24% to $1.43 in 2023, then jumped by 111.19% to $3.02 in 2024, then advanced by 10.6% to $3.34 in 2025, then surged by 32.63% to $4.43 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $4.43 (Q1 2026), $3.34 (Q4 2025), and $4.08 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 4.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.43 |
| Dec 31, 2025 | 3.34 |
| Sep 30, 2025 | 4.08 |
| Jun 30, 2025 | -11.74 |
| Mar 31, 2025 | -1.52 |
| Dec 31, 2024 | 3.02 |
| Sep 30, 2024 | 3.42 |
| Jun 30, 2024 | 2.49 |
| Mar 31, 2024 | -0.23 |
| Dec 31, 2023 | 1.43 |
| Sep 30, 2023 | 2.14 |
| Jun 30, 2023 | 1.52 |
| Mar 31, 2023 | 1.04 |
| Dec 31, 2022 | -3.84 |
| Sep 30, 2022 | -0.31 |
| Jun 30, 2022 | 0.55 |
| Mar 31, 2022 | 0.03 |
| Dec 31, 2021 | -0.54 |
| Sep 30, 2021 | -0.86 |
| Jun 30, 2021 | -6.11 |
| Mar 31, 2021 | 2.09 |
| Dec 31, 2020 | 2.33 |
| Sep 30, 2020 | 2.64 |
| Jun 30, 2020 | 2.06 |
| Mar 31, 2020 | -2.82 |
| Dec 31, 2019 | 1.29 |
| Sep 30, 2019 | 1.78 |
| Jun 30, 2019 | 4.56 |
| Mar 31, 2019 | 1.47 |
| Dec 31, 2018 | 2.64 |
| Sep 30, 2018 | 2.41 |
| Jun 30, 2018 | 1.50 |
| Mar 31, 2018 | 0.75 |
| Dec 31, 2017 | 3.79 |
| Sep 30, 2017 | 1.03 |
| Jun 30, 2017 | 1.72 |
| Mar 31, 2017 | 1.41 |
| Dec 31, 2016 | 1.91 |
| Sep 30, 2016 | 1.45 |
| Jun 30, 2016 | 1.85 |
| Mar 31, 2016 | 1.21 |
| Dec 31, 2015 | 1.32 |
| Sep 30, 2015 | 1.39 |
| Jun 30, 2015 | 1.40 |
| Mar 31, 2015 | 1.12 |
| Dec 31, 2014 | 1.30 |
| Sep 30, 2014 | 0.41 |
| Jun 30, 2014 | 0.70 |
| Mar 31, 2014 | -1.58 |
| Dec 31, 2013 | 0.90 |
| Sep 30, 2013 | 1.23 |
| Jun 30, 2013 | 0.69 |
| Mar 31, 2013 | 0.71 |
| Dec 31, 2012 | 3.28 |
| Sep 30, 2012 | 0.55 |
| Jun 30, 2012 | 0.45 |
| Mar 31, 2012 | 0.48 |
| Dec 31, 2011 | 0.79 |
| Sep 30, 2011 | 0.69 |
| Jun 30, 2011 | 0.71 |
| Mar 31, 2011 | 0.48 |
| Dec 31, 2010 | 0.61 |
| Sep 30, 2010 | 0.69 |
| Jun 30, 2010 | 0.71 |